Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.

Communications biology - 19 Dec 2024

Jia Xiaoting, Tian Jingjie, Chen Pingping, Dong Jing, Li Lei, Chen Danyang, Zhang Jianlei, Liao Dongjiang, He Zhimin, Luo Kai

Abstract excerpt

Inevitable gefitinib resistance is the biggest bottleneck in current treatment and the mechanisms are not fully understood. Here, we observe that PFTK1 (also named CDK14) is significantly enhanced in NSCLC with gefitinib resistance. And the upregulation of PFTK1 is negatively associated with progression-free survival (PFS) in NSCLC patients who receive gefitinib treatment. Further study suggests that gefitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gefitinib

Share to Mice, Nude

Share to Wnt Signaling Pathway

Source

Open in PubMed Open full text

Identifiers

PMID: 39702755
DOI: 10.1038/s42003-024-07339-3
PMCID: PMC11659392

Genes

CDK14
DNMT3B
EGFR
LRP6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.PMID 39702755Read ↗

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.Semantic proximity Read ↗

KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cellsSemantic proximity Read ↗

Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex.Semantic proximity Read ↗

DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma.Semantic proximity Read ↗

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.Semantic proximity Read ↗

Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway.Semantic proximity Read ↗

Knockdown of TRAF1 in NSCIC Contributes Gefitinib Sensitivity by Promoting G2/M Cell Cycle ArrestSemantic proximity Read ↗

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.Semantic proximity Read ↗

Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancerSemantic proximity Read ↗

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancerSemantic proximity Read ↗

Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.Semantic proximity Read ↗

Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.